How should intermenstrual bleeding in a reproductive‑age woman be evaluated and managed?

Evaluation and Management of Intermenstrual Bleeding in Reproductive-Age Women

Begin with a pregnancy test and transvaginal ultrasound combined with transabdominal imaging to identify structural causes before initiating any hormonal therapy. 1

Initial Diagnostic Evaluation

Mandatory First Steps

• Perform a urine β-hCG test immediately to exclude pregnancy, as this is the most critical differential diagnosis in any reproductive-age woman with abnormal bleeding. 2, 1

• Order combined transvaginal and transabdominal ultrasound with Doppler as the first-line imaging study to identify structural causes including polyps, adenomyosis, leiomyomas, endometrial hyperplasia, and malignancy. 1

• Perform a speculum examination to visualize the cervix and vagina, ruling out cervical polyps, cervicitis, cervical erosion, or vaginal lesions as the bleeding source. 1, 3

Laboratory Assessment

• Obtain thyroid-stimulating hormone (TSH) and prolactin levels to assess for endocrine causes of ovulatory dysfunction that may present as intermenstrual bleeding. 2, 1

• Consider coagulation studies (CBC, PT/PTT, von Willebrand factor) if the patient reports heavy menstrual bleeding in addition to intermenstrual spotting, has a personal or family history of bleeding disorders, or fails medical therapy. 3, 4

Age-Specific Indications for Endometrial Sampling

Women ≥35 Years

• Proceed directly to endometrial biopsy in any woman aged ≥35 years with intermenstrual bleeding, regardless of ultrasound findings, because the risk of endometrial hyperplasia and carcinoma rises significantly in this age group. 5

Women <35 Years

• Perform endometrial biopsy if any of the following risk factors are present: 5

  • Chronic anovulation or polycystic ovary syndrome
  • Obesity (BMI >30 kg/m²)
  • Diabetes mellitus or hypertension
  • Prolonged unopposed estrogen exposure
  • Tamoxifen therapy
  • Family history of Lynch syndrome or endometrial cancer

• Endometrial biopsy is also indicated when ultrasound shows endometrial thickness ≥10 mm or when bleeding persists despite appropriate medical therapy. 1, 5

Advanced Imaging When Initial Ultrasound Is Inadequate

• Order saline-infusion sonohysterography (SIS) when focal lesions are suspected or when standard transvaginal ultrasound cannot adequately visualize the endometrium; SIS provides 96–100% sensitivity for detecting endometrial pathology and reliably distinguishes polyps from diffuse thickening. 1, 5

• Proceed to hysteroscopy with directed biopsy when initial endometrial sampling is nondiagnostic, inadequate, or when symptoms persist despite a negative work-up; hysteroscopy allows direct visualization and targeted sampling of lesions that blind biopsy may miss. 1, 5

Medical Management

First-Line Hormonal Therapy

• Prescribe combined hormonal contraceptives (CHCs) or progestin-only contraception as first-line therapy for intermenstrual bleeding due to ovulatory dysfunction after structural causes have been excluded. 2, 1

• Select CHCs when contraception is desired and there are no contraindications to estrogen (personal history of thromboembolism, stroke, migraine with aura, uncontrolled hypertension, or breast cancer). 1

• Use cyclic progestin therapy (e.g., medroxyprogesterone acetate 10 mg daily for 10–14 days each month) for patients who cannot use estrogen-containing products. 1

Alternative Medical Options

• Consider the levonorgestrel-releasing intrauterine device (LNG-IUD) as a highly effective option that achieves minimal systemic hormone absorption and is particularly suitable when systemic exposure is undesirable or in patients with cardiovascular contraindications. 1

• Avoid NSAIDs and tranexamic acid in patients with cardiovascular disease due to increased risk of myocardial infarction and thrombosis. 1

Common Clinical Pitfalls

• Do not assume structural pathology is absent based solely on a normal ultrasound; failure to respond to appropriate hormonal therapy should prompt reassessment with saline-infusion sonohysterography or hysteroscopy. 2

• Do not accept an inadequate or negative endometrial biopsy as reassuring in a symptomatic patient, especially those ≥35 years or with risk factors; office endometrial biopsies have a 10% false-negative rate. 5

• Do not initiate hormonal contraception without first performing transvaginal ultrasound in women with intermenstrual bleeding, as this may mask symptoms of underlying structural pathology including malignancy. 6, 1

• Do not overlook pregnancy complications (ectopic pregnancy, threatened abortion, trophoblastic disease) as causes of intermenstrual bleeding; these require immediate diagnosis and management. 3

Escalation to Surgical Management

• Refer to gynecology for surgical intervention when medical management fails, is contraindicated, or not tolerated; options include endometrial ablation or hysterectomy. 1

• Immediate gynecologic referral is mandatory if endometrial sampling reveals hyperplasia with atypia or malignancy. 1

Special Populations

Adolescents

• In the first 1–2 years after menarche, irregular bleeding is physiologic due to immaturity of the hypothalamic-pituitary-ovarian axis; however, treatment is necessary to prevent anemia and improve quality of life. 2

• Use transabdominal ultrasound rather than transvaginal ultrasound in adolescents who have not engaged in vaginal intercourse. 2

Perimenopausal Women

• Maintain a lower threshold for endometrial sampling in perimenopausal women because anovulatory cycles become increasingly common, resulting in unopposed estrogen exposure that markedly raises the risk of endometrial hyperplasia and carcinoma. 1